DREADDing proglucagon neurons: a fresh look at metabolic regulation by the brain.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 28218623.
- Also identified by DOI 10.1172/JCI92845 and PMC identifier 5330747.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Glucagon-like peptide 1 receptor (GLP-1R) signaling in the CNS has been linked to reduced food intake, lower body weight, improved glucose homeostasis, and activation of CNS stress axes. GLP-1 is produced by cells that express proglucagon (GCG); however, the stimuli that activate GCG+ neurons are not well known, which has made understanding the role of this neuronal population in the CNS a challenge. In this issue of the JCI, Gaykema et al. use designer receptors exclusively activated by designer drugs (DREADD) technology to specifically activate GCG+ neurons in mouse models. While activation of GCG+ neurons did reduce food intake, and variably decreased hepatic glucose production, other GLP-1-associated effects were not observed - e.g., activation of stress axes or stimulation of insulin secretion - in response to GCG+ neuron activation. The authors have provided a valuable model to study this set of neurons in vivo, and their results provide new insights into the function of GCG+ neural activity in the brain and raise questions that will move research on this clinically relevant neural system forward.
Medical subject headings
- Brain
- Drug Design
- Glucagon-Like Peptide-1 Receptor
- Neurons
- Proglucagon
- Glucagon-Like Peptide-1 Receptor Agonists